An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With RA
N/A
Terminated
NCT02557295
| Condition | Rheumatoid Arthritis |
|---|
| Phase | N/A |
|---|
| Sponsor | Celltrion |
|---|
| Status | Terminated |
|---|
| Enrollment | 248 participants |
|---|
| Start date | Dec 17, 2013 |
|---|
| Completion date | Mar 2, 2020 |
|---|
| Results posted | Feb 5, 2024 |
|---|
Summary
An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of RemsimaTM in Patients with Rheumatoid Arthritis.
The Number and Percentage of Patients With the Following Adverse of Events of Special Interest (ESI)
Duration of study participation (up to 5 years) · Participants
| Remsima | 5 Participants |
|---|
| Switch to Remsima I | 1 Participants |
|---|
| Switch to Remsima II | 1 Participants |
|---|
| Remicade | 0 Participants |
|---|
| Switch to Remicade I | 0 Participants |
|---|
| Switch to Remicade II | 0 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.